UPS to acquire Bomi Group

ATLANTA — UPS plans to acquire Bomi Group, a multinational healthcare logistics provider.

The transaction will add temperature-controlled facilities in 14 countries and nearly 3,000 highly-skilled Bomi Group team members to the UPS Healthcare network in Europe and Latin America.

“As a leading global healthcare logistics company, Bomi enhances our portfolio of services and accelerates our journey to become the number one provider of complex healthcare logistics,” said executive vice-president and president of UPS International, healthcare and supply chain solutions, Kate Gutmann. “UPS Healthcare and Bomi Group employees share similar values and our cultures are firmly rooted in a relentless focus on quality. The combination of our two teams will significantly improve our healthcare customers’ ability to continue to develop and deliver life-saving innovations.”

Since 1985, Bomi Group has provided services for the Medtech and Pharma sectors with a customized and tailored approach. Key Bomi Group leaders, including CEO Marco Ruini, will continue in their roles after the transaction closes.

The acquisition will add more than 350 temperature-controlled vehicles and 391 square kilometres to the UPS healthcare global footprint, offering customers access to faster shipping times, greater production flexibility, and offerings to help them attract new business.

The acquisition will help in the delivery of next-generation pharmaceutical and biologic treatments that increasingly require time-critical and temperature-sensitive logistics.

“We are focused on building healthcare logistics capabilities and services that allow our customers to deliver the newest healthcare innovations,” said UPS healthcare president Wes Wheeler. “We are excited to combine Bomi’s talent, expertise and capabilities with UPS Healthcare — together, we will provide unmatched solutions to our customers, powered by UPS’s integrated, global smart logistics network.”

The transaction is expected to close by the end of the year, subject to regulatory review and approval.